Dear Reader,
Over the past 25 years, I've made it my mission to speak up when something feels off in the markets.
A month before the dot-com bubble burst, I published a warning essentially saying: "This can't last."
In 2008, I rang the alarm on housing calling the fall of Bear Stearns and Lehman Brothers.
I've exposed shady CEOs, market frauds, and financial bubbles before most investors saw the cracks.
Eventually, CNBC gave me a nickname I didn't ask for: "The Prophet."
But what I see happening right now... it's much bigger.
Some are even calling it, "The bubble to burst them all."
And that's why I've stepped forward in a way I never have before... to show you exactly what's coming... and how to stay on the right side of it.
Because if I'm right again – and I've put together all my proof for you – this may be your final chance to prepare.
Click here to see the full details while there's still time.
Regards,
Whitney Tilson
Editor, Stansberry's Investment Advisory
AbbVie Call Options Spike 2,599%: Tracking the Big Bet
Author: Jeffrey Neal Johnson. Posted: 1/16/2026.
Key Points
- Institutional investors are showing high confidence, as evidenced by a significant increase in bullish market activity ahead of financial results.
- The strategic expansion into the metabolic health and obesity markets provides a long-term pathway to diversify the total revenue stream.
- A comprehensive, voluntary federal agreement helps ensure the organization can focus on research and domestic manufacturing with great certainty.
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public. On Jan. 15, 2026, AbbVie Inc. (NYSE: ABBV) experienced one of these events. Daily call option volume for the healthcare giant surged to 2,599% of its historical average. This spike in bullish activity suggests that informed investors are positioning for a significant move. With the stock trading near $216.66, the volume implies a belief that a breakthrough or positive financial surprise may be imminent.
Traders use call options to profit from a rising share price. When volume jumps by more than 2,500%, it is rarely a coincidence: institutional investors often have access to deep research and sophisticated models that help them anticipate market shifts. Looking at AbbVie's near-term calendar highlights several likely catalysts that could explain the sudden rush into calls.
Betting on a February Beat: The Q4 Earnings Window
Which stock will the White House buy next? (Ad)
Insiders in Washington have already bought massive stakes in three tiny resource firms, driving them up as much as 200% overnight. Now, the man who recommended MP Materials before the White House bought (making 100% for his followers) is naming the next stocks he believes the government will target.
Get the names and tickers right here – free of charge.The most immediate reason for the surge in options is the upcoming fourth-quarter 2025 earnings report, which AbbVie is estimated to release on Feb. 4, 2026. Institutional confidence appears high because the company has established a pattern of outperformance over the past year. In every quarter of 2025, AbbVie beat analyst estimates and raised its full-year guidance. The company currently expects adjusted earnings per share (EPS) of $10.61 to $10.65 for the full year.
Investors have been particularly impressed with how management has handled product transitions. For years the market worried that the decline of the blockbuster drug Humira would hurt AbbVie's results. Recent data suggest the company's plan to replace that revenue is working:
- Humira sales fell 55.7% in the most recent quarter due to biosimilar competition.
- Skyrizi and Rinvoq posted combined sales growth of more than 40%.
- These newer drugs have helped stabilize the company's total revenue base.
If management provides a strong outlook for 2026 on the February call, it would help justify the massive call volume currently in play. Traders appear to be betting that AbbVie's growth drugs will continue to outperform, setting up another beat-and-raise scenario.
The $100 Billion Pledge
Strategic growth and a new regulatory agreement are also driving bullish sentiment. On Jan. 12, 2026, AbbVie reached a voluntary agreement with the federal administration that runs for three years. Under the deal, AbbVie committed to a $100 billion investment in U.S. research, development and manufacturing over the next 10 years and secured a three-year exemption from new tariffs and federal drug-pricing mandates. That policy certainty reduces political risk and makes it easier for institutions to buy large blocks of stock with confidence.
This regulatory win coincides with AbbVie's entry into the high-growth obesity market. On Jan. 15, 2026, the company said it had completed a first human trial for GUB014295, a long-acting amylin analog designed to treat obesity — one of the fastest-growing sectors in healthcare.
By entering obesity, AbbVie could see multiple expansions as investors price in higher growth. The company is also awaiting an FDA decision on its Parkinson's disease candidate, Tavapadon, in the first half of 2026. Those clinical and commercial catalysts are likely what options traders are trying to get ahead of.
Dividend King Status: 53 Years of Reliable Growth
While new growth projects could drive a higher share price, AbbVie's fundamentals provide a strong safety net. AbbVie's analyst community currently holds a Moderate Buy consensus on the stock. The average 12-month price target is $247.84, implying roughly 14% upside from today's price. The stock's forward price-to-earnings ratio (P/E) of 17.60 is attractive, particularly as the company adds more high-growth drugs to its portfolio.
Income-oriented investors also find comfort in AbbVie's status as a Dividend King. The company has increased its dividend for 53 consecutive years. The current quarterly dividend is $1.73 per share (about a 3.19% yield), resulting in an annual dividend of roughly $6.93. Large institutions own 70.23% of the company, signaling that many investors value AbbVie for its reliable income and defensive qualities. That high level of institutional ownership can create a valuation floor, making the stock less likely to fall sharply while traders wait for the next catalyst.
Positioning for a Breakout: The Road to $250
The sudden 2,599% surge in call option volume is a clear sign that sophisticated investors are preparing for a potential breakout. This activity reflects a convergence of positive events: a more certain regulatory environment, entry into the obesity market, and consistent earnings growth. AbbVie has moved beyond reliance on legacy drugs and is emerging as a more diversified leader in immunology and metabolic health.
For investors seeking a mix of dependable income and the potential for meaningful price appreciation, the current market signals are notable. The smart money is showing increased interest in AbbVie, and the upcoming February earnings report could be the catalyst that starts a new rally.
This email content is a paid advertisement provided by Stansberry Research, a third-party advertiser of DividendStocks.com and MarketBeat.
This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
If you need assistance with your newsletter, please don't hesitate to contact our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. U.S.A..
0 Response to "A month before the crash"
Post a Comment